Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain
- PMID: 28132521
- PMCID: PMC5488349
- DOI: 10.1089/hum.2016.109
Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain
Abstract
GM2 gangliosidoses, including Tay-Sachs disease and Sandhoff disease, are lysosomal storage disorders caused by deficiencies in β-N-acetylhexosaminidase (Hex). Patients are afflicted primarily with progressive central nervous system (CNS) dysfunction. Studies in mice, cats, and sheep have indicated safety and widespread distribution of Hex in the CNS after intracranial vector infusion of AAVrh8 vectors encoding species-specific Hex α- or β-subunits at a 1:1 ratio. Here, a safety study was conducted in cynomolgus macaques (cm), modeling previous animal studies, with bilateral infusion in the thalamus as well as in left lateral ventricle of AAVrh8 vectors encoding cm Hex α- and β-subunits. Three doses (3.2 × 1012 vg [n = 3]; 3.2 × 1011 vg [n = 2]; or 1.1 × 1011 vg [n = 2]) were tested, with controls infused with vehicle (n = 1) or transgene empty AAVrh8 vector at the highest dose (n = 2). Most monkeys receiving AAVrh8-cmHexα/β developed dyskinesias, ataxia, and loss of dexterity, with higher dose animals eventually becoming apathetic. Time to onset of symptoms was dose dependent, with the highest-dose cohort producing symptoms within a month of infusion. One monkey in the lowest-dose cohort was behaviorally asymptomatic but had magnetic resonance imaging abnormalities in the thalami. Histopathology was similar in all monkeys injected with AAVrh8-cmHexα/β, showing severe white and gray matter necrosis along the injection track, reactive vasculature, and the presence of neurons with granular eosinophilic material. Lesions were minimal to absent in both control cohorts. Despite cellular loss, a dramatic increase in Hex activity was measured in the thalamus, and none of the animals presented with antibody titers against Hex. The high overexpression of Hex protein is likely to blame for this negative outcome, and this study demonstrates the variations in safety profiles of AAVrh8-Hexα/β intracranial injection among different species, despite encoding for self-proteins.
Keywords: AAV; Tay-Sachs disease; adeno-associated virus; gene therapy; hexosaminidase; intracranial delivery.
Conflict of interest statement
No competing financial interests exist.
Figures





Similar articles
-
Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.Mol Ther. 2020 Oct 7;28(10):2150-2160. doi: 10.1016/j.ymthe.2020.06.021. Epub 2020 Jun 19. Mol Ther. 2020. PMID: 32592687 Free PMC article.
-
Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.Exp Neurol. 2015 Jan;263:102-12. doi: 10.1016/j.expneurol.2014.09.020. Epub 2014 Oct 5. Exp Neurol. 2015. PMID: 25284324 Free PMC article.
-
Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.Gene Ther. 2015 Feb;22(2):181-9. doi: 10.1038/gt.2014.108. Epub 2014 Dec 4. Gene Ther. 2015. PMID: 25474439
-
[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].Yakugaku Zasshi. 2013;133(2):269-74. doi: 10.1248/yakushi.12-00199. Yakugaku Zasshi. 2013. PMID: 23370522 Review. Japanese.
-
GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.Int J Mol Sci. 2020 Aug 27;21(17):6213. doi: 10.3390/ijms21176213. Int J Mol Sci. 2020. PMID: 32867370 Free PMC article. Review.
Cited by
-
Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis.Mol Ther Methods Clin Dev. 2022 Mar 16;25:170-189. doi: 10.1016/j.omtm.2022.03.011. eCollection 2022 Jun 9. Mol Ther Methods Clin Dev. 2022. PMID: 35434178 Free PMC article.
-
AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice.Nature. 2022 Apr;604(7905):343-348. doi: 10.1038/s41586-022-04533-3. Epub 2022 Mar 23. Nature. 2022. PMID: 35322228 Free PMC article.
-
Therapeutic Strategies For Tay-Sachs Disease.Front Pharmacol. 2022 Jul 5;13:906647. doi: 10.3389/fphar.2022.906647. eCollection 2022. Front Pharmacol. 2022. PMID: 35865957 Free PMC article. Review.
-
Biochemical Correction of GM2 Ganglioside Accumulation in AB-Variant GM2 Gangliosidosis.Int J Mol Sci. 2023 May 24;24(11):9217. doi: 10.3390/ijms24119217. Int J Mol Sci. 2023. PMID: 37298170 Free PMC article.
-
Myeloid-derived β-hexosaminidase is essential for neuronal health and lysosome function: implications for Sandhoff disease.bioRxiv [Preprint]. 2024 Oct 22:2024.10.21.619538. doi: 10.1101/2024.10.21.619538. bioRxiv. 2024. PMID: 39484433 Free PMC article. Preprint.
References
-
- Gravel RA, Kaback MM, Proia RL, et al. . The GM2 gangliosidoses. In: Scriver C, Beaudet AL, Sly WS, Valle D, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001
-
- Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet 2012;13:307–335 - PubMed
-
- Johnson WG, Desnick RJ, Long DM, et al. . Intravenous injection of purified hexosaminidase A into a patient with Tay–Sachs disease. Birth Defects Orig Artic Ser 1973;9:120–124 - PubMed
-
- Enns GM, Huhn SL. Central nervous system therapy for lysosomal storage disorders. Neurosurg Focus 2008;24:E12 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous